AMSTERDAM, February 16, 2011 /PRNewswire/ -- In the news release, "Amsterdam Molecular Therapeutics Reports Full Year Results 2010" issued on 16 Feb 2011 06:00 GMT, by Amsterdam Molecular Therapeutics B.V AEX:AMT over PR Newswire, we are advised by a representative of the company that the full year figures should have been included in the dissemination. Complete, corrected release follows
Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, today reported its results for the year to December 31, 2010.
- Glybera(R) Marketing Authorisation Application remains on track with European Medicines Agency (EMA); - Responses to Day 120 questions submitted in November 2010; - Day 180 list of Outstanding Issues now received; - Raised EUR14.3 million through private placement; - Novel biomarker for Glybera(R) activity identified; - Diagnostic gene chip for LPLD developed by AMT's collaborator, Progenika, obtained CE Mark; - Hemophilia Phase I/II study underway, being led by St Jude Children's Hospital and UCL Hospital; data from initial patients showed safe, Stable expression; - DMD program progressing with US Orphan Drug Status granted and up to EUR 4 million Senter Novem funding; - Porphyria program funding through EU grant now finalized; - GDNF program progressing following renegotiation of collaboration agreement with Amgen; and - New collaboration initiated with consortium led by Institut Pasteur to develop Sanfilippo gene therapy.
Jorn Aldag, Chief Executive Officer of AMT, commented: "We are excited by the key milestones achieved in 2010: our lead product Glybera(R) is progressing towards market approval and we are looking forward, with confidence, to the Regulatory Agency's decision. We have continued, also, to make good progress in our other pipeline programs, on both the R&D and partnering fronts."
Lipoprotein Lipase Deficiency (LPLD)
The advance of AMT's lead product, Glybera(R) towards market approval was the key focus of the Group's activities during 2010. The regulatory process continues to progress on schedule. Following the filing of Glybera(R) with the European Medicines Agency (EMA) as a treatment for lipoprotein lipase deficiency (LPLD), the agency conducted its initial review of the Glybera(R) registration dossier in early 2010 and sent the Day 120 List of Questions to AMT in May. AMT submitted its response to the EMA in November 2010, based in part on additional data and analyses from patients previously treated with Glybera(R), including new data available from the last clinical trial and its one-year extension. The EMA restarted evaluation on November 26 (Day 121), and following the normal centralized review procedure, AMT has received, at Day 180, a significantly reduced list of outstanding items. We are now in the process of compiling the responses and expect to submit answers to the EMA by end of the first quarter and believe to be on track for a mid 2011 response on marketing approval.
Because AMT's technology can be applied equally to a wide range of other genetic diseases, the success of Glybera(R) would validate AMT's approach for its other pipeline products, targeting a range of orphan diseases and diseases with large patient populations, in each case where there is high unmet medical need, including Parkinson's disease, hemophilia, Duchenne muscular dystrophy (DMD) and acute intermittent porphyria (AIP).
The hemophilia B program has entered a Phase I/II clinical study, led by our partners St Jude Children's Research Hospital, Memphis, Tennessee, and University College London (UCL) Hospital, London, UK. Initial data presented at the American Society of Hematology (ASH) conference in Florida in December 2010 showed that dose-dependent, safe, stable, and persistent expression in patients has been observed.
Our collaboration with FIMA in Pamplona, Spain, to develop a gene therapy for acute intermittent porphyria (AIP) is progressing very well, and has generated positive pre-clinical data. The program is now entering toxicology studies and a Phase I/II study is scheduled to begin in early 2012. Total grant funding of EUR 3.3 million for this project has been secured from the EU, with EUR1.1 million assigned to AMT, supporting our financial commitment to this project.
Duchenne Muscular Dystrophy
The DMD program continues to progress, with up to EUR 4 million of financial support from Senter Novem, which covers 35% of development costs through to completion of the Phase I/II study. In September 2010, the US FDA granted our gene therapy for DMD Orphan Drug status. This complements the Orphan Drug status granted to the same program by the EMA covering Europe in 2009.
AMT has successfully renegotiated the terms of its collaborative agreement with Amgen covering the use of GDNF in gene therapies. AMT now has the ability to explore development of additional indications, including orphan diseases, alongside the development of Parkinson's disease. The University of Lund, Sweden, is performing preclinical studies in Parkinson's disease models for this program, the results of which are encouraging.
Immediately after the year-end, AMT announced a collaboration with Institut Pasteur and the Association Francaise contre les Myopathies (AFM) to develop a gene therapy for the rare lysosomal disorder, Sanfilippo B for which Institut Pasteur has achieved preclinical proof of concept. Under the agreement, AMT will receive funding to manufacture the product using its AAV vector technology to progress the program through a Phase I/II study. Thereafter, AMT will have an option to acquire full commercial rights to the program.
In October 2010, AMT successfully raised EUR 14.3 million of new funds, before expenses (EUR13.3 million net of costs) via a private placement of ordinary shares. These funds together with our existing cash resources take AMT comfortably through the assessment process of Glybera. The Company also expects to generate significant additional revenue from commercializing Glybera and from developing its collaborations with other parties. Taking these additional funding sources into account, AMT believes it will have sufficient cash resources to meet its operational requirements.
The total net income for the year ended December 31, 2010 amounted to EUR 1.4 million, a EUR 1.0 million increase compared to the total net income for the year ended December 31, 2009, which amounted to EUR 0.4 million. These revenues represent grant income from the Dutch government and the European Union.
Research and development expenditure totaled EUR 16.4 million, compared to EUR 13.2 million in 2009, an increase of EUR 3.2 million reflecting the ongoing level of activity to support the filing of Glybera, as well as ongoing development on AMT's other projects, including the Duchenne program (which is partly funded by the investment credit from Senter Novem) and reflecting the activities financed by the grants described above. In addition, research and development expenditure in 2010 included the EUR 0.5 million of impairment charges and the largest part of the EUR 0.5 million increase in charges relating to share-based incentive schemes, both of which represent non-cash items.
General and administrative costs decreased to EUR 4.1 million, from EUR 4.9 million in 2009. This decrease reflected the lower level of advisory costs in 2010, compared to 2009, as well as the fact that 2009 contained certain reorganization costs.
AMT's operating loss rose to EUR 19.1 million for 2010, from EUR 17.8 million for 2009, an increase of EUR 1.3 million. This increase can be largely accounted for by certain non-cash items amounting to EUR 1.0 million, comprising an increase of EUR 0.5 million in charges relating to share-based incentive schemes, a EUR 0.3 million charge relating to impairment charges on certain intangible assets following the termination of a 2008 collaboration agreement, and a EUR 0.2 million charge in respect of the impairment of certain leasehold improvements. After excluding for these non-cash, non-recurring items, the operating loss in 2010 would have been broadly equivalent to the operating loss for 2009.
Finance income and costs
Net finance income fell to EUR 0.5 million compared to EUR 0.6 million in 2009, reflecting the lower average cash balances of the Group during 2010 during a period when interest rates available on cash deposits remained low. In addition, finance costs increased to EUR 0.5 million compared to EUR 0.0 million, reflecting the interest charge payable on the 2009 convertible bond, together with foreign exchange movements on currency accounts. Of these finance costs, EUR 0.2 million relates to non-cash items.
Result for the Year and Loss per Share
Total net loss for the year ended December 31, 2010 amounted to EUR 19.1 million, compared to the net loss for the year ended December 31, 2009, which amounted to EUR 17.2 million, an increase of EUR 1.9 million. The increase in the net loss includes an increase in non-cash charges of EUR 1.2 million described within the 'Operating loss' and 'Finance income and costs' paragraphs above. The loss per share amounted to EUR 1.13 for 2010 compared to EUR 1.17 for 2009. The basic and diluted loss per share are the same because the company is loss-making in both periods.
Cash Flow and Cash Position
Cash and cash equivalents amounted to EUR 17.9 million at December 31, 2010, a decrease of EUR 4.8 million or 21% compared to EUR 22.6 million at December 31, 2009. The decrease in cash and cash equivalents is mainly the result of cash used in operating activities amounting to EUR 17.7 million in 2010 (2009: EUR16.5 million), offset by net cash generated from financing activities of EUR 13.4 million.
The cash used in operating activities represents our operational loss adjusted for non-cash items such as share-based payment expenses and changes in working capital.
The cash flow from financing activities amounted to EUR 13.4 million reflecting the issue of new shares in October 2010, compared to EUR 4.8 million in 2009, which principally represented the drawdown of the convertible loan.
Shareholders' equity amounted to EUR 13.5 million at December 31, 2010 compared to EUR 18.4 million at December 31, 2009. A total number of 23,512,225 shares were issued and outstanding at December 31, 2010.
The company expects its existing cash resources, together with the net cash inflows that it expects to generate during 2011 from partnering activities and from the commercialization of Glybera(R) that would follow a successful MAA submission, to be sufficient to fund its operations for at least the next 12 months from the date of publication of the audited consolidated annual accounts, which is expected to be on March 4, 2011. In reaching this conclusion, the Management of AMT has considered the uncertainty inherent in forecasting future net cash inflows, and believes that its expectations, as described above, are reasonable.
To discuss these results, AMT's management will conduct a conference call at 3:30 PM CET, which will also be webcast.
To participate in the conference call, please call one of the following telephone numbers 15 minutes prior to the event, using access code 3705648: +44(0)20-7806-1956 for the UK; +1-212-444-0413 for the US; and +31(0)20-707-5510 for the Netherlands. Following the results presentation, the lines will be opened for a question and answer session. A replay of the call will be available following the event.
About Amsterdam Molecular Therapeutics
AMT is a world leader in the development of human gene based therapies. The company's lead product Glybera(R), a gene therapy for the treatment of lipoprotein lipase deficiency (LPLD), is currently under review by the European Medicines Agency (EMA). If approved, Glybera will be the first gene therapy product to be marketed in Europe. AMT also has a product pipeline of several gene therapy products in development for hemophilia B, Duchenne muscular dystrophy, acute intermittent porphyria, and Parkinson's disease. Using adeno-associated viral (AAV) derived vectors as the delivery vehicle of choice for therapeutic genes, the company has been able to design and validate probably the world's first stable and scalable AAV manufacturing platform. This proprietary platform can be applied to a large number of rare (orphan) diseases caused by one faulty gene and allows AMT to pursue its strategy of focusing on this sector of the industry. AMT was founded in 1998 and is based in Amsterdam. Further information can be found at http://www.amtbiopharma.com.
Certain statements in this press release are "forward-looking statements" including those that refer to management's plans and expectations for future operations, prospects and financial condition. Words such as "strategy," "expects," "plans," "anticipates," "believes," "will," "continues," "estimates," "intends," "projects," "goals," "targets" and other words of similar meaning are intended to identify such forward-looking statements. Such statements are based on the current expectations of the management of AMT only. Undue reliance should not be placed on these statements because, by their nature, they are subject to known and unknown risks and can be affected by factors that are beyond the control of AMT. Actual results could differ materially from current expectations due to a number of factors and uncertainties affecting AMT's business. AMT expressly disclaims any intent or obligation to update any forward-looking statements herein except as required by law.
Consolidated Balance sheet 2010 2009 Asset Non-current assets Intangible assets 2,917 3,008 Property plant and equipment 1,286 1,756 4,202 4,764 Current assets Receivables from related parties 35 34 Social securities and other taxes 409 414 Other taxes 198 469 Cash and cash equivalents 17,859 22,624 18,500 23,541 Total assets 22,703 28,305 Equity Shareholders equity 13,659 18,410 Liabilities Non-current liabilities Financial lease liabilities 221 259 Debt to related party 4,622 4,723 Other non-current liabilities - - 4,842 4,982 Current liabilities Trade payables 1,556 1,182 Social security and other taxes 196 215 Other current liabilities 2,449 3,516 4,201 4,913 Total liabilities 9,044 9,895 Total equity and liabilities 22,703 28,305 Consolidated income statement 2010 2009 Other inocme 1,448 355 Total net income 1,448 355 Research and development cost (16,404) (13,241) General and administrative costs (4,113) (4,913) Total operating costs (20,517) (18,154) Operating result (19,069) (17,799) Finance income 472 647 Finance costs (521) (23) (49) 624 Result before corporate income taxes (19,118) (17,175) Corporate income taxes Result for the year (19,118) (17,175) 31.12.2010 31.12.2009 Cash flow from operating activities Result before corporate income tax (19,118) (17,175) adjustments for: - Depreciation and amortization 684 688 - Impairment of assets 472 - Derivative result (220) - Exchange result 127 - Share-based payment expenses 957 440 - Changes in working capital (440) 165 - Interest (income)/expense 142 (624) Cash used in operations (17,396) (16,506) Interest paid (256) (23) Net cash generated from operating activities (17,652) (16,529) Cash flow from investing activities Purchases of property, plant and equipment (386) (106) Purchases of intangible fixed assets (208) (511) Interest received 71 857 Net cash used in investing activities (523) 240 Cash flow from financing activities Capital contribution shareholders 13,410 40 Convertible loans drawn down, net of costs 4,723 Net cash generated from financing activities 13,410 4,763 Net (decrease)/increase in cash, cash (4,765) (11,526) equivalents and other bank overdrafts Cash, cash equivalents at the beginning of the year 22,624 34,150 Cash, cash equivalents at the end of the year 17,859 22,624
SOURCE Amsterdam Molecular Therapeutics B.V